However, these could be early symptoms of a condition called hyperkalaemia (high levels of potassium in the blood) It affects ...

AstraZeneca’s hyperkalaemia treatment Lokelma has been approved in Europe, a relief to the company after two years of delay to the potential blockbuster. Formerly known as ZS-9, Lokelma (sodium ...

Vifor Pharma has gained final European marketing approval for its hyperkalaemia treatment Veltassa. The approval is a major milestone for the Switzerland-headquartered speciality pharma company ...

Lokelma is used for the treatment of hyperkalaemia, a condition characterized by elevated potassium levels in the blood. It is an adult drug used for those with high potassium and are marketed ...

Hyperkalaemia, characterised by elevated potassium levels, affects 6-7% of the global population, posing severe risks to those with chronic kidney disease. Key symptoms include shortness of breath ...